Identification of a novel polymorphic enhancer of the human CYP3A4 gene.

CYP3A4, the most abundant form of cytochrome P450 in the human adult liver, shows wide interindividual variation in its activity. This variability is thought to be caused largely by transcriptional and genetic factors, yet the underlying mechanisms are poorly understood. The purpose of this study was to clarify the mechanisms controlling the CYP3A4 gene transcription and to search for genetic polymorphisms in the 5'-flanking region of the CYP3A4 gene. Transient transfection of human hepatoma HepG2 cells and of normal human hepatocytes with a series of CYP3A4 promoter-luciferase reporter plasmids revealed that a region from -11.4 to -10.5 kilobases, designated the constitutive liver enhancer module of CYP3A4 (CLEM4), was important for the constitutive activation of the CYP3A4 gene. Gel shift assay using nuclear extracts prepared from HepG2 cells showed that HNF-1alpha, HNF-4alpha, USF1, and AP-1 interacted with CLEM4. Furthermore, the introduction of mutations into their binding sites demonstrated that essentially all sites were required for the maximal enhancer activity. Screening for genetic polymorphisms within CLEM4 in genomic DNA from French persons, we identified the novel variant, TGT insertion between -11,129 and -11,128 (-11,129_-11,128insTGT), whose allele frequency was 3.1%. The -11,129_-11,128insTGT resulted in the disruption of USF1 binding and a 36% reduction of the enhancer activity. These results suggest that CLEM4 is a constitutive enhancer of the CYP3A4 gene in the liver and that -11,129_-11,128insTGT may at least partly contribute to the interindividual variability of CYP3A4 expression.

[1]  M. Ingelman-Sundberg,et al.  Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[2]  Wooin Lee,et al.  The orphan nuclear receptor HNF4α determines PXR- and CAR-mediated xenobiotic induction of CYP3A4 , 2003, Nature Medicine.

[3]  E. Schuetz,et al.  Genetic contribution to variable human CYP3A-mediated metabolism. , 2002, Advanced drug delivery reviews.

[4]  Jun Yokota,et al.  Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[5]  B. Goodwin,et al.  Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. , 2002, Molecular pharmacology.

[6]  A. Okey,et al.  Modeling of human hepatic CYP3A4 enzyme kinetics, protein, and mRNA indicates deviation from log-normal distribution in CYP3A4 gene expression , 2002, European Journal of Clinical Pharmacology.

[7]  H. Yamazaki,et al.  Hepatocyte nuclear factor-1alpha is a causal factor responsible for interindividual differences in the expression of UDP-glucuronosyltransferase 2B7 mRNA in human livers. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[8]  Ann Daly,et al.  Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. , 2002, Pharmacogenetics.

[9]  T. Kamataki,et al.  Novel Transcriptional Regulation of the Human CYP3A7Gene by Sp1 and Sp3 through Nuclear Factor κB-like Element , 2001 .

[10]  J. Hudson,et al.  The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. , 2001, Pharmacogenetics.

[11]  T. Willson,et al.  The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[12]  U. Brinkmann,et al.  Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. , 2001, Pharmacogenetics.

[13]  J. Castell,et al.  Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: A study using adenovirus‐mediated antisense targeting , 2001, Hepatology.

[14]  M. Loriot,et al.  Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population. , 2001, Pharmacogenetics.

[15]  A. Berkenstam,et al.  Functionally conserved xenobiotic responsive enhancer in cytochrome P450 3A7. , 2001, Biochemical and biophysical research communications.

[16]  B. Neuschwander‐Tetri,et al.  Humanized xenobiotic response in mice expressing nuclear receptor SXR , 2000, Nature.

[17]  A. Paterson,et al.  Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. , 2000, Pharmacogenetics.

[18]  B. Goodwin,et al.  The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. , 1999, Molecular pharmacology.

[19]  T. Kawamoto,et al.  Phenobarbital-Responsive Nuclear Translocation of the Receptor CAR in Induction of the CYP2B Gene , 1999, Molecular and Cellular Biology.

[20]  M. Ingelman-Sundberg,et al.  Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region. , 1999, Biochemical and biophysical research communications.

[21]  P. Nowell,et al.  Association of CYP3A4 genotype with treatment-related leukemia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Lehmann,et al.  The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. , 1998, The Journal of clinical investigation.

[23]  P. Beaune,et al.  Expression and localization of CYP3A4 and CYP3A5 in human lung. , 1997, American journal of respiratory cell and molecular biology.

[24]  A. Li,et al.  Substrates of human hepatic cytochrome P450 3A4. , 1995, Toxicology.

[25]  H. Shih,et al.  Two CACGTG Motifs with Proper Spacing Dictate the Carbohydrate Regulation of Hepatic Gene Transcription (*) , 1995, The Journal of Biological Chemistry.

[26]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[27]  E. Schuetz,et al.  Expression of cytochrome P450 3A in amphibian, rat, and human kidney. , 1992, Archives of biochemistry and biophysics.

[28]  Tsonwin Hai,et al.  Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[29]  M. Sari,et al.  Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae. , 1990, Biochemistry.

[30]  M. Soma,et al.  Fetus-specific expression of a form of cytochrome P-450 in human livers. , 1990, Biochemistry.

[31]  T. Aoyama,et al.  Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. , 1989, The Journal of biological chemistry.

[32]  P. Watkins,et al.  Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. , 1987, The Journal of clinical investigation.

[33]  P. Beaune,et al.  Isolation and sequence determination of a cDNA clone related to human cytochrome P-450 nifedipine oxidase. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[34]  R. Roeder,et al.  Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. , 1983, Nucleic acids research.

[35]  T. Kamataki,et al.  Hepatocyte nuclear factor-4 alpha/gamma and hepatocyte nuclear factor-1 alpha as causal factors of interindividual difference in the expression of human dihydrodiol dehydrogenase 4 mRNA in human livers. , 2003, Pharmacogenetics.

[36]  J. Lehmann,et al.  Diverse roles of the nuclear orphan receptor CAR in regulating hepatic genes in response to phenobarbital. , 2002, Molecular pharmacology.

[37]  T. Kamataki,et al.  Novel transcriptional regulation of the human CYP3A7 gene by Sp1 and Sp3 through nuclear factor kappa B-like element. , 2001, The Journal of biological chemistry.

[38]  T. Rebbeck,et al.  More about: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. , 2000, Journal of the National Cancer Institute.

[39]  K. Thummel,et al.  In vitro and in vivo drug interactions involving human CYP3A. , 1998, Annual review of pharmacology and toxicology.

[40]  S. Wrighton,et al.  The human hepatic cytochromes P450 involved in drug metabolism. , 1992, Critical reviews in toxicology.

[41]  T. Shimada,et al.  Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. , 1989, Proceedings of the National Academy of Sciences of the United States of America.